Das Zentrum
Multiple Sklerose Zentrum Dresden
Patienteninformation
Kontaktinformation
Behandlungsteam
Studienteam
Neuropsychologie
Mobilitätszentrum
Das Mobilitätszentrum
Ganganalyse
Sprunganalyse
DIERS
EMIQ
Forschungsprojekte
Neuroimmunologisches Labor
Das NIL
Neurofilament-Leichtketten Analyse
Autonomes & Neuroendokrinologisches Funktionslabor
Das ANF
Untersuchungsmethoden
MS Living Lab
Management & Science
Team Management & Science
Projekte
eHealth & Analytics
MSDS 3D
MSDS Klinik & Praxis
MS-HRS
MTRS
MS Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
MS Tag 2025
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Spenden
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Immunzellkalender 2025
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
Deutsch
Deutsch
English
Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" Multiple Sclerosis and Related Disorders 2017
NIL
Jahr
Publikationsjahr
2018
Autoren
Autorenliste der Publikation
Akgün K, Kaufmann M, Ziemssen T.
Verlag
Publisher-Information
Mult Scler Relat Disord 2018;22:68-69.
Link
Zur Publikation (externer Server)
https://doi.org/10.1016/j.msard.2018.03.012
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Neuroimmunologie
Treatments
NIL
2018
Whole brain volume loss is associated with a short-term disability progression in relapse-activity free multiple sclerosis
Multiple Sclerosis
Jahr
2025
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response
NIL
Jahr
2025
Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing.
MS Treatments
Jahr
2025
CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany
MS Treatments
Jahr
2025
RECLAIM—A retrospective, multicenter observational study aimed at enabling the development of artificial intelligence-driven prognostic models for disease progression in multiple sclerosis
MASC
Jahr
2025
